Skip to content
OpenCapital
Get started

Thermo Fisher Scientific TMO Cash & Equivalents

Cash & Equivalents at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$1.02B+49.0%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$509M-2.7%
GLW
CorningGLW
$1.76B+29.1%
Revvity logo
RevvityRVTY
$861.47M-24.3%
Kewaunee Scientific Corporation logo
Kewaunee Scientific CorporationKEQU
$9.95M-42.0%
Danaher logo
DanaherDHR
$5.7B+186%

Other financials

Income statement

See full
Revenue$11.0B+6.2%
Operating income$1.9B+8.6%
Net income$1.7B+9.6%
EPS (diluted)$4.43+11.3%

Balance sheet

See full
Total debt$43.2B+16.6%
Total equity$51.9B+5.2%
Total assets$113.28B+14.4%

Cash flow

See full
Operating cash flow$1.2B+64.9%
CapEx$376.0M+3.9%
Free cash flow$816.0M+126%

Valuation

See full
Market cap$198.93B+22.3%
Enterprise value$238.81B+22.2%
P/E29.1×+4.4×
P/S4.6×-0.9×

Profitability

See full
Gross margin58.3%—
Operating margin17.2%+0.8pp
Net margin15.2%+1.0pp
FCF margin15.7%-2.1pp

Returns & leverage

See full
Return on equity13.5%-0.2pp
Debt / equity0.8×+0.1×
Current ratio1.5×-0.2×

Where this comes from

Reported directly by Thermo Fisher Scientific in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Thermo Fisher Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Thermo Fisher Scientific's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Thermo Fisher Scientific's cash & equivalents?
Thermo Fisher Scientific (TMO) reported cash & equivalents of $3.28B in Q1 2026.
How has Thermo Fisher Scientific's cash & equivalents changed year-over-year?
Thermo Fisher Scientific's cash & equivalents decreased by 21.4% year-over-year, from $4.17B to $3.28B.
What is the long-term trend for Thermo Fisher Scientific's cash & equivalents?
Over 5 years (2020 to 2025), Thermo Fisher Scientific's cash & equivalents has grown at a -0.9% compound annual growth rate (CAGR), from $10.34B to $9.88B.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.